WuXi Biologics, Fresenius partner ahead of biosimilar boom
Endpoints NewsTopic alignment 88
WuXi Biologics and German drugmaker Fresenius have reached one of the largest biosimilar deals to date ahead of what some in the industry have called an upcoming “golden decade” for such products. ...
Filed under
- Biosimilarsmatch 88
Teva and Samsung Bioepis Enter Into Licensing Agreement to Commercialize Etanercept and Infliximab Biosimilars in the U.S.
Big Molecule WatchTopic alignment 85
Keytruda biosimilars are coming — but they face an uphill battle
BioPharma DiveTopic alignment 92
FDA Approves Xbrane’s LUCAMZI™, a Biosimilar to LUCENTIS®
Big Molecule WatchTopic alignment 90
How the Biosimilars Access and Affordability Act Redefines IRA Delays
The Center for BiosimilarsTopic alignment 92